Lipids & metabolic liver disease
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
Authors' conclusion
Chiglitazar administration is associated with a significant reduction in CAP values in T2D patients with MASLD, suggesting its potential as a dual therapeutic approach for both conditions.
Study context
- Population
- T2D patients with MASLD in a real-world clinical setting
- Participants
- 235 patients31 matched pairs
- Exposure
- Chiglitazar vs other glucose-lowering medications
- Chiglitazarn = 40
- Non-chiglitazarn = 195reference
- Outcome
- Changes in controlled attenuation parameter (CAP, hepatic steatosis) and liver stiffness measurement (LSM, fibrosis)
- Follow-up
- 24 weeks
Methodological detailsreal-world, 1:1 propensity score matching
- Real-world
- 1:1 propensity score matching
Main finding
As reported in the abstract
Chiglitazar
−28.38
adjusted mean · 95% CI 36.11–-20.65 · dB/m
Non-chiglitazar
−16.74
adjusted mean · CI −24.47–-9.01 · dB/m
Between-group difference (CAP), dB/m (CI)P value
Chiglitazarvs Non-chiglitazargreater CAP reduction with chiglitazar
−11.64(−22.38 to −0.90)
P = 0.038Difference in LS mean (LSM) (CI)P value
Between Chiglitazar and Non-chiglitazarLSM changes similar between groups
0.11(−1.04 to 0.82)
P = 0.813Observational data: associations, not effects.
Secondary outcomes
Controlled attenuation parameter (CAP) effect by subgroup (sex, age, BMI, concomitant SGLT2i or GLP-1 RA)
- Beneficial effect of chiglitazar consistent across subgroups
- all P for interaction > 0.05
Original publication
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study. Diabetes Metab. Published 21 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →